CCCCMEDIUM SIGNALFINANCIAL10-K

CCCC's operating cash burn increased substantially while the company maintained adequate liquidity and reduced total liabilities by 23%.

The meaningful deterioration in operating cash flow suggests higher spending on clinical development activities, though this may reflect natural progression of their pipeline programs. The company appears to have maintained financial flexibility with improved cash position and reduced debt burden, providing runway for continued operations.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

CCCC experienced substantially higher operating cash outflows, indicating increased investment in clinical programs or operational expansion. However, the company's balance sheet improved with cash reserves growing 34% to $75M and total liabilities declining 23% to $103M. The combination of higher cash burn but stronger balance sheet positioning suggests the company successfully raised capital while reducing financial obligations, though investors should monitor cash runway given the elevated spending rate.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
-51.5%
-$65.2M→-$98.7M

Operating cash flow fell 51.5% — earnings quality concerns; investigate working capital changes and non-cash items.

Cash & Equivalents
Balance Sheet
+34.4%
$55.5M→$74.6M

Cash position surged 34.4% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-26.9%
$45.2M→$33.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-23.3%
$133.6M→$102.5M

Liabilities reduced 23.3% — deleveraging improves balance sheet strength and financial flexibility.

Accounts Receivable
Balance Sheet
-22.6%
$3.1M→$2.4M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
+18.8%
$216.0M→$256.6M

Equity base grew 18.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
In some cases, forward-looking statements can be identified by terminology such as will, may, should, could, expects, intends, plans, aims, anticipates, believes, estimates, predicts, potential, continue, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
These risks include, among others: We are a clinical-stage biopharmaceutical company and have incurred significant losses since our inception.
We expect to incur losses over at least the next several years and may never achieve or maintain profitability.
Our net loss was $105.0 million and $105.3 million for the years ended December 31, 2025 and 2024, respectively.
While we are a clinical-stage company and have commenced clinical trials of several product candidates, we have never obtained regulatory approval to commercialize any of our product candidates.
We have ongoing collaborations with Roche, Betta Pharma, and Merck KGaA.
Potential changes in government programs and changes in government staffing or funding levels could affect various aspects of our business, and our degrader clinical candidates that require government review or approval may experience delays in obtaining requisite authorizations.
International trade policies, including tariffs, sanctions, and trade barriers may adversely affect our business, financial condition and results of operations and prospects.
This Form 10-K may also contain trademarks, service marks, and trade names of third parties, including, without limitation, our collaboration partners Roche, Biogen, Merck KGaA, and Pfizer Inc., which are the property of their respective owners.
Our strategy is to develop degraders that modulate clinically validated disease pathways with best-in-class or first-in-class potential to address significant unmet patient needs.
REMOVED
These risks include, among others: We are a clinical-stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception.
To date, we have not generated any revenue from product sales.
We expect to continue to incur significant expenses and increasing operating losses for at least the next several years and may never achieve or maintain profitability.
Our net loss was $105.3 million and $132.5 million for the years ended December 31, 2024 and 2023, respectively.
While we are a clinical-stage company and have commenced clinical trials of several product candidates, we have never completed a clinical trial of any of our product candidates.
We have ongoing collaboration agreements with Roche, Betta Pharma, Merck, and MKDG, as well as collaboration agreements with Biogen MA, Inc., or Biogen and Calico, whose research terms expired on June 30, 2023 and March 13, 2023, respectively.
This Form 10-K may also contain trademarks, service marks, and trade names of third parties, which are the property of their respective owners.
Our degrader approaches are focused on bringing the E3 ligase in close enough proximity to the disease-causing protein, so that the E3 ligase can tag it for destruction.
We have the capability to design two different types of protein degraders depending on the target.
The first type are MonoDAC degraders, which function by binding to E3 ligases and creating a new surface on the E3 ligases that enhances the binding of the E3 ligases to target proteins.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →